跳到正文
Isomorphic Labs·· 2026-01-20精选AI 评分60

Isomorphic Labs 与强生达成跨模态多靶点研究合作

Isomorphic Labs Enters into a Research Collaboration with Johnson & Johnson

AI 导读

Isomorphic Labs 宣布与强生达成跨模态、多靶点研究合作,将把其 AI 优先的药物发现方法与强生的靶点生物学和药物开发经验结合。Isomorphic Labs 的基础药物设计引擎可针对小分子、抗体、肽和分子胶等多种模态生成候选药物,本次合作还将覆盖大分子与生物药设计。

推荐理由

原文披露双方合作覆盖多靶点与多种药物模态,可据此观察AI药物发现平台与大型药企的分工及能力边界。

正文 · 原文

Isomorphic Labs announces a cross-modality, multi-target research collaboration with Johnson & Johnson. This partnership brings together Iso’s AI-first approach to drug discovery with Johnson & Johnson’s expertise in drug discovery and development. 

Isomorphic Labs’ foundational drug design engine is capable of generating drug candidates against challenging targets across a range of modalities such as small molecules, antibodies, peptides and molecular glues. This collaboration will leverage this multi-modality discovery capability, including large molecule and biologics design.

Read more in the news release below.‍

‍

Johnson & Johnson

This partnership combines Isomorphic Labs’ pioneering AI capabilities with Johnson & Johnson’s expertise in target biology and drug discovery.

Read more

来源:Isomorphic Labs · isomorphiclabs.com